Home › Gastroparesis › NCT03876288

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

Who can join

All ages · All sexes

Inclusion:

* Patients with the symptoms (Sx) of drug refractory gastroparesis
* Disordered nutrition by standardized assessment
* Ability to assess current symptom status
* Ability to measure other medical conditions

Exclusion:

* Anatomic obstruction of the GI Tract
* Pregnancy
* Inability of patient or guardian to sign informed consent, if needed
* Psychiatric disorders precluding assessment and treatment of the patient's GI condition

About the study

GOLDEN is a longitudinal database of patients with the symptoms (Sx) of gastroparesis (Gp) who were seen and recorded at the University of Louisville from 2012 and is ongoing. Patients are enrolled and followed by sequential numbers and may include legacy patients seen at other centers by some of the same team and who are reported as part of the series. Outcome relate to patients Sx, survival, quality of life and other measures as detailed below, over time. The study tracks patients regardless of treatment but specifically focuses on GI Neuromodulation (gastric electrical stimulation - GES), Immunotherapy (IVIG), and Pyloric therapies (pyloroplasty, endoscopic). If treatments were administered GOLDEN allows for examination and stratification of outcome by groups both at baseline and at follow up.

What is being tested

• GI Neuromodulation (device)
• Immunotherapy (drug)
• Pyloric Therapies (procedure)

Sponsor: University of Louisville · Participants: 3,000 · Started: Jan 1, 2013

Contact the study team

• Thomas Abell, MD · Phone: (502)852-6991

Official record on ClinicalTrials.gov — NCT03876288

Locations in the U.S.

Conditions

• Gastroparesis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.